Loading company…
Riskpilot
← Back to search
Sign in
Get full access
Pharmolys AB
AB
Active
Org 5568511678
Brommavägen 4 2tr Lgh 1201
Research and experimental development on natural sciences and engineering · NACE 7210
Est. 2011
0 employees
Watchlist
Share
Overview
Financials
People & ownership
Related companies
Revenue 2025
SEK 175K
-71% vs 2024
EBITDA margin
-42.9%
-120% vs 2024
Equity ratio
72.9%
Financial strength
Net profit 2025
SEK 2K
-99% vs 2024
EBITDA — year on year
SEK millions
0M
-0M
-1M
-1M
-1M
0M
2021
0M
0%
2022
0M
0%
2023
0M
0%
2024
0M
0%
2025
Key figures
Annual report 2025
Revenue
SEK 175K
-71%
EBITDA
SEK -75K
-120%
Net profit
SEK 2K
-99%
Total assets
SEK 856K
-16%
Equity
SEK 624K
+0%
Employees
0
—
Company information
Legal name
Pharmolys AB
Org number
5568511678
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
29 april 2011
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-08-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Medicinsk konsultation, rådgivning, utbildning samt import och export av medicinsk utrustning.
Contact
Address
Brommavägen 4 2tr Lgh 1201
Phone
+468889914
Email
moustaphah@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Visit risika.com
Explore
Companies in Research and experimental development on natural sciences and engineering
Companies in Stockholm
All Sweden companies
Revenue
SEK millions
0M
0M
1M
1M
1M
0M
2021
0M
2022
0M
2023
1M
2024
0M
2025
EBITDA
SEK millions
0M
0M
1M
1M
1M
0M
2021
0M
2022
0M
2023
0M
2024
0M
2025
Income statement
SEK thousands
Item
2021
2022
2023
2024
2025
Revenue
155
267
450
596
175
Staff expenses
—
—
—
—
−5
EBITDA
90
194
374
372
−75
Depreciation & amort.
−0
—
—
—
—
EBIT
90
194
374
372
−75
Net financials
—
−0
−1
−0
−2
Profit before tax
89
142
273
272
25
Tax
−13
−32
−62
−67
−23
Net profit
76
111
210
205
2
Balance sheet
SEK thousands
Item
2021
2022
2023
2024
2025
Total assets
246
436
845
1 021
856
Equity
176
207
417
622
624
Long-term debt
0
—
—
—
—
Short-term debt
71
178
275
146
82
Total debt
71
178
275
146
82
Financial ratios
5-year trend
EBITDA margin
-42.9%
This company
15.8%
Market median
-372% vs market
2021
2025
Equity ratio
72.9%
This company
38.2%
Market median
+91% vs market
2021
2025
Return on equity
0.3%
This company
18.4%
Market median
-98% vs market
2021
2025
Net profit margin
0.9%
This company
8.1%
Market median
-89% vs market
2021
2025
Asset turnover
0.20×
This company
1.12×
Market median
-82% vs market
2021
2025
Debt / equity
0.37×
This company
0.62×
Market median
+40% vs market
2021
2025
Annual reports & filings
Annual report 2025
Filed via Bolagsverket / SCB · Period 2024-09-01 – 2025-08-31
View
PDF
Annual report 2024
Filed via Bolagsverket / SCB · Period 2023-09-01 – 2024-08-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2022-09-01 – 2023-08-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2021-09-01 – 2022-08-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2020-09-01 – 2021-08-31
View
PDF
Management
Actively employed in the business
No data on file.
Board of directors
Non-executive oversight
Name
Role
Member since
Current (3)
AH
Amir Hassan
Deputy Board Member
2022
AM
Adam Mohamed Hassan
Deputy Board Member
2022
MM
Moustapha Mohamed Moustapha Hassan
Board of Directors
2022
Shareholders
As of last annual report
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
Company hierarchy
No registered parent or subsidiaries
Board network connections
Board members of Pharmolys AB also hold positions in
0
other companies.
Person
Role here
Other companies
Amir Hassan
Deputy Board Member
0 companies
Adam Mohamed Hassan
Deputy Board Member
0 companies
Moustapha Mohamed Moustapha Hassan
Board of Directors
0 companies